Skip to Content
Merck
  • Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.

Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.

Biomaterials (2014-09-03)
Amy H Van Hove, Michael-John G Beltejar, Danielle S W Benoit
ABSTRACT

Despite the recent expansion of peptide drugs, delivery remains a challenge due to poor localization and rapid clearance. Therefore, a hydrogel-based platform technology was developed to control and sustain peptide drug release via matrix metalloproteinase (MMP) activity. Specifically, hydrogels were composed of poly(ethylene glycol) and peptide drugs flanked by MMP substrates and terminal cysteine residues as crosslinkers. First, peptide drug bioactivity was investigated in expected released forms (e.g., with MMP substrate residues) in vitro prior to incorporation into hydrogels. Three peptides (Qk (from Vascular Endothelial Growth Factor), SPARC113, and SPARC118 (from Secreted Protein Acidic and Rich in Cysteine)) retained bioactivity and were used as hydrogel crosslinkers in full MMP degradable forms. Upon treatment with MMP2, hydrogels containing Qk, SPARC113, and SPARC118 degraded in 6.7, 6, and 1 days, and released 5, 8, and, 19% of peptide, respectively. Further investigation revealed peptide drug size controlled hydrogel swelling and degradation rate, while hydrophobicity impacted peptide release. Additionally, Qk, SPARC113, and SPARC118 releasing hydrogels increased endothelial cell tube formation 3.1, 1.7, and 2.8-fold, respectively. While pro-angiogenic peptides were the focus of this study, the design parameters detailed allow for adaptation of hydrogels to control peptide release for a variety of therapeutic applications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MMP-2 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Thioanisole, ReagentPlus®, ≥99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Calcein-AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N-Ethyldiisopropylamine solution, suitable for peptide synthesis, ~2 M in 1-methyl-2-pyrrolidinone
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N-Ethyldiisopropylamine, BASF quality, ≥98.0%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
Amphotericin B, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Matrix Metalloproteinase-2 human, >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
2,2′-(Ethylenedioxy)diethanethiol, 95%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
DIC, purum, ≥98.0% (GC)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
HBTU, ≥98.0% (T)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Triisopropylsilane, 98%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N,N-Diisopropylethylamine, purified by redistillation, 99.5%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Piperazine, ReagentPlus®, 99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
DIC, 99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N,N-Diisopropylethylamine, 99.5%, biotech. grade
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Piperazine, BioUltra, anhydrous, ≥99.0% (T)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Diisopropylcarbodiimide solution, 1 M in THF
SKU
Pack Size
Availability
Price
Quantity